Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID).

Witt M, Grunke M, Proft F, Baeuerle M, Aringer M, Burmester G, Chehab G, Fiehn C, Fischer-Betz R, Fleck M, Freivogel K, Haubitz M, Kötter I, Lovric S, Metzler C, Rubberth-Roth A, Schwarting A, Specker C, Tony HP, Unger L, Wassenberg S, Dörner T, Schulze-Koops H; German Registry of Autoimmune Diseases (GRAID) Investigators.

Lupus. 2013 Oct;22(11):1142-9. doi: 10.1177/0961203313503912.

PMID:
24057058
2.

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).

Tony HP, Burmester G, Schulze-Koops H, Grunke M, Henes J, Kötter I, Haas J, Unger L, Lovric S, Haubitz M, Fischer-Betz R, Chehab G, Rubbert-Roth A, Specker C, Weinerth J, Holle J, Müller-Ladner U, König R, Fiehn C, Burgwinkel P, Budde K, Sörensen H, Meurer M, Aringer M, Kieseier B, Erfurt-Berge C, Sticherling M, Veelken R, Ziemann U, Strutz F, von Wussow P, Meier FM, Hunzelmann N, Schmidt E, Bergner R, Schwarting A, Eming R, Hertl M, Stadler R, Schwarz-Eywill M, Wassenberg S, Fleck M, Metzler C, Zettl U, Westphal J, Heitmann S, Herzog AL, Wiendl H, Jakob W, Schmidt E, Freivogel K, Dörner T; GRAID investigators.

Arthritis Res Ther. 2011 May 13;13(3):R75. doi: 10.1186/ar3337.

3.

Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry.

Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, Bonnet C, Cacoub P, Cantagrel A, de Bandt M, Fain O, Fautrel B, Gaudin P, Godeau B, Harlé JR, Hot A, Kahn JE, Lambotte O, Larroche C, Léone J, Meyer O, Pallot-Prades B, Pertuiset E, Quartier P, Schaerverbeke T, Sibilia J, Somogyi A, Soubrier M, Vignon E, Bader-Meunier B, Mariette X, Gottenberg JE; Club Rhumatismes et Inflammation.

Arthritis Rheum. 2010 Aug;62(8):2458-66. doi: 10.1002/art.27541.

4.

The effects of rituximab on the lipid profile of patients with active systemic lupus erythematosus: results from a nationwide cohort in Spain (LESIMAB).

Fernández-Nebro A, Marenco JL, López-Longo F, Galindo M, Hernández-Cruz BE, Narváez J, Rúa-Figueroa I, Raya-Alvarez E, Zea A, Freire M, Sánchez-Atrio AI, García-Vicuña R, Pego-Reigosa JM, Manrique-Arija S, Nieves-Martín L, Carreño L; LESIMAB GROUP.

Lupus. 2014 Sep;23(10):1014-22. doi: 10.1177/0961203314534909. Epub 2014 May 15.

PMID:
24833667
5.

Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study.

Fernández-Nebro A, de la Fuente JL, Carreño L, Izquierdo MG, Tomero E, Rúa-Figueroa I, Hernández-Cruz BE, Narváez J, Ucar E, Olivé A, Zea A, Fernández-Castro M, Raya-Álvarez E, Pego-Reigosa JM, Freire M, Martínez-Taboada VM, Pérez-Venegas J, Sánchez-Atrio AI, Villa-Blanco I, Manrique-Arija S, López-Longo FJ, Carreira PE, Martínez-Pérez R, García-Vicuña R.

Lupus. 2012 Sep;21(10):1063-76. doi: 10.1177/0961203312446627. Epub 2012 Jul 11.

PMID:
22786985
6.

Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.

Jovancevic B, Lindholm C, Pullerits R.

Lupus. 2013 Jun;22(7):664-74. doi: 10.1177/0961203313485489. Epub 2013 Apr 23. Review.

PMID:
23612795
7.

Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.

Ramos-Casals M, García-Hernández FJ, de Ramón E, Callejas JL, Martínez-Berriotxoa A, Pallarés L, Caminal-Montero L, Selva-O'Callaghan A, Oristrell J, Hidalgo C, Pérez-Alvarez R, Micó ML, Medrano F, Gómez de la Torre R, Díaz-Lagares C, Camps M, Ortego N, Sánchez-Román J; BIOGEAS Study Group.

Clin Exp Rheumatol. 2010 Jul-Aug;28(4):468-76. Epub 2010 Aug 30.

PMID:
20525449
8.

[Long-term follow-up of patients with refractory systemic lupus erythematosus during rituximab treatment].

Tsanian MÉ, Solov'ev SK, Torgashina AV, Aleksandrova EN, Radenska-Lopovok SG, Nikolaeva EV, Khrennikova IaB, Nasonov EL.

Ter Arkh. 2014;86(5):40-9. Russian.

PMID:
25026801
9.

Pediatric systemic lupus erythematosus in Thammasat University Hospital.

Pusongchai T, Jungthirapanich J, Khositseth S.

J Med Assoc Thai. 2010 Dec;93 Suppl 7:S283-93.

PMID:
21294427
10.

Rituximab therapy for juvenile-onset systemic lupus erythematosus.

Nwobi O, Abitbol CL, Chandar J, Seeherunvong W, Zilleruelo G.

Pediatr Nephrol. 2008 Mar;23(3):413-9. Epub 2007 Dec 19.

11.

[Rituximab in pediatric patients with systemic lupus erythematosus].

Pavón-Sánchez JM, Sánchez-Sánchez LM.

Gac Med Mex. 2013 Sep-Oct;149(5):492-6. Spanish.

12.

Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis.

Borba HH, Wiens A, de Souza TT, Correr CJ, Pontarolo R.

BioDrugs. 2014 Apr;28(2):211-28. doi: 10.1007/s40259-013-0074-x. Review.

PMID:
24190520
13.

[Rituximab therapy for severe pediatric systemic lupus erythematosus].

Su GX, Wu FQ, Wang F, Zhou ZX, Huang XL, Lu J.

Zhonghua Er Ke Za Zhi. 2012 Sep;50(9):697-704. Chinese.

PMID:
23158822
14.

Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review.

Cobo-Ibáñez T, Loza-Santamaría E, Pego-Reigosa JM, Marqués AO, Rúa-Figueroa I, Fernández-Nebro A, Cáliz Cáliz R, López Longo FJ, Muñoz-Fernández S.

Semin Arthritis Rheum. 2014 Oct;44(2):175-85. doi: 10.1016/j.semarthrit.2014.04.002. Epub 2014 Apr 13. Review.

PMID:
24830791
15.
16.

Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy.

Roccatello D, Sciascia S, Rossi D, Alpa M, Naretto C, Baldovino S, Menegatti E, La Grotta R, Modena V.

Nephrol Dial Transplant. 2011 Dec;26(12):3987-92. doi: 10.1093/ndt/gfr109. Epub 2011 Mar 8.

17.

Safety and efficacy of combined cyclophosphamide and rituximab treatment in recalcitrant childhood lupus.

Ale'ed A, Alsonbul A, Al-Mayouf SM.

Rheumatol Int. 2014 Apr;34(4):529-33. doi: 10.1007/s00296-013-2896-8. Epub 2013 Nov 12.

PMID:
24218286
18.

Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus.

Catapano F, Chaudhry AN, Jones RB, Smith KG, Jayne DW.

Nephrol Dial Transplant. 2010 Nov;25(11):3586-92. doi: 10.1093/ndt/gfq256. Epub 2010 May 11.

PMID:
20466686
19.

Rituximab induces a rapid and sustained remission in Colombian patients with severe and refractory systemic lupus erythematosus.

Pinto LF, Velásquez CJ, Prieto C, Mestra L, Forero E, Márquez JD.

Lupus. 2011 Oct;20(11):1219-26. doi: 10.1177/0961203311409273. Epub 2011 Jul 22.

PMID:
21784778
20.

Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry.

Iaccarino L, Bartoloni E, Carli L, Ceccarelli F, Conti F, De Vita S, Ferraccioli G, Galeazzi M, Gatto M, Gerli R, Govoni M, Gremese E, Iuliano A, Mansutti E, Moroni G, Mosca M, Nalli C, Naretto C, Padovan M, Palma L, Raffiotta F, Roccatello D, Tincani A, Valesini G, Zen M, Doria A.

Clin Exp Rheumatol. 2015 Jul-Aug;33(4):449-56. Epub 2015 Jun 8.

PMID:
26053285

Supplemental Content

Support Center